IMV News and Press, IMV Inc. From 05/12/21

The following slide deck was published by IMV Inc. in conjunction with their 2021 Q1 earnings call. For further details see: IMV Inc. 2021 Q1 - Results - Earnings Call Presentation

IMV (IMV): Q1 GAAP EPS of -$0.10 beats by $0.03.Revenue of $0.07M (flat Y/Y) misses by $0.01M.Press Release For further details see: IMV EPS beats by $0.03, misses on revenue

Phase 2B study in r/r DLBCL to begin in Q2 of this year New investigator-initiated study of maveropepimut-S in breast cancer to be initiated this summer First in human dual-targeted immunotherapy (DPX-SurMAGE) study in bladder cancer later in the year Two recog...

IMV continues to add industry expertise with appointment of Dr. Michael Kalos, an internationally recognized expert in T cell therapy and immunotherapy James Hall to retire at the AGM after 11 years as a board member IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TS...

Study will evaluate maveropepimut-S (formerly known as DPX-Survivac) with an aromatase inhibitor, with/without radiotherapy or cyclophosphamide prior to surgery Analysis of tumor tissue in this study will provide key insights for the therapeutic potential of maveropepimut-S in...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV’s executive management team will be participating in the 2021 Bloom Burton & Co. Healthcare Investor Virtual Conference which will be held April 20 and April 21, 2021. ...

Merck & Co. is a large legacy company that makes a profit, pays a consistent dividend, and is a familiar and dependable company. That sometimes makes for boring. Analysts have a consensus target price in the mid-$90s while it might be undervalued by over 50%. Merck develops an...

Following the feedback from the FDA, IMV ([[IMV]] -2.2%) in agreement with Merck ([[MRK]] +0.4%) is set to evaluate maveropepimut-S (DPX-Survivac) in combination with Keytruda in recurrent/refractory diffuse large B cell lymphoma (r/rDLBCL).Maveropepimut-S, an experimental immunotherapy,...

SOS (SOS) +36%.Titan Medical (TMDI) +25%.CBAK Energy Technology (CBAT) +21%.Altimeter Growth (AGCUU) +18%.CA Healthcare Acquisition (CAHCU) +16%.TransMedics (TMDX) +16%. as FDA Advisory Panel has issued a favorable vote in support of approval of the OCS Heart System.Altimeter Growth (AGC...

The two companies agreed on final design of the new Phase 2B study Patient population and clinical endpoints aligned with FDA guidance for potential path to accelerated approval IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a ...